Despite being used for myopia management for many years, significant controversy exists in both literature and clinical optometric practice regarding the optimal concentration of atropine. The LAMP study sheds light on this mystery by investigating efficacy of 0.05%, 0.025% and 0.01% atropine for slowing myopia progression.
Pathologic myopia is one of the major causes of blindness worldwide. Degenerative changes associated with high myopia, including posterior staphyloma formation and scleral thinning, are caused by the progressive elongation of globe axial length and stretching of the sclera, choroid and retina. The aim of this meta-analysis was to investigate and quantitatively define the efficacy of PSR in controlling axial elongation and refraction progression.